

## futibatinib tablet (LYTGOBI)

### Diagnoses Considered for Coverage:

- Cholangiocarcinoma
  - Intrahepatic
  - Extrahepatic

### Coverage Criteria:

#### For diagnosis listed above:

- Disease is unresectable, locally advanced, or metastatic, **and**
- Presence of FGFR2 gene fusion or other rearrangements, **and**
- Being used as a single agent, **and**
- Patient has received at least 1 prior therapy for cholangiocarcinoma, **and**
- Dose does not exceed 20 mg once daily.

**Coverage Duration:** one year

#### References:

1. LYTGOBI(R) oral tablets [prescribing information]. Taiho Oncology Inc, Princeton, NJ. 2022.

Effective Date: 11/29/2023